Drug Trial Radar · NCT06615375
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Nov 12, 2024
Primary completion
Apr 14, 2026
Study completion Sep 18, 2026
Sponsor
- Lead sponsor
- LimmaTech Biologics AGIndustry
- Sponsor type
- Industry
- Collaborators
- Emory University; Johns Hopkins Bloomberg School of Public Health; Children's Hospital Medical Center, Cincinnati
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In this challenge study, the bioconjugate candidate vaccine Shigella4V2 will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella sonnei strain compared to participants receiving placebo.
Conditions
- Shigellosis
Interventions
Shigella4V2Biological
Shigella4V2 is a tetravalent bioconjugate vaccine
PlaceboBiological
Phosphate-buffered saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate that the Shigella4V2 bioconjugate vaccine protects against shigellosis following challenge with the wild type S. sonnei 53G strain.Time frame: To be evaluated post-challenge during the inpatient period (Day 56 through Day 65) in vaccinees vs. placebo
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Hope Clinic of Emory University
Atlanta, Georgia
Johns Hopkins Center for Immunization Research
Baltimore, Maryland
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.